The rise of Sildenafil initially sparked a boom for the drug industry, nevertheless recent developments present a uncertain outlook for shareholders. Off-patent versions are eating into revenue, and ongoing patent challenges add further complexity to the situation. While specific companies might still benefit from related offerings, the general tra